spacer
home > epc > spring 2009 > avoiding obstacles
PUBLICATIONS
European Pharmaceutical Contractor

Avoiding Obstacles

Clinical trial supplies management can be a notoriously difficult logistical task. The opportunity for deviation is further enhanced by having to manage the movement of cold chain material (typically classified as 2°-8°C). This article will look at the most common obstacles encountered when procuring and moving cold chain products, with a focus on comparator products.

More and more clinical trials are utilising comparator drugs and, especially in oncology, most of the existing products are cold chain. There is much to consider when moving cold chain products: gone are the days of throwing in a few gel packs and hoping for the best. The standard expected now is much higher, and correctly so. Regulatory and logistical requirements often shape the delivery protocol. Medicines requiring controlled temperature storage conditions must be distributed in a manner that always ensures that their quality will not be adversely affected. The World Health Organization’s policy on Good Distribution Practice (GDP) broadly mirrors the attitudes published by bodies such as the Food and Drug Administration (FDA), European Medicines Evaluation Agency (EMEA) and the Medicines and Healthcare products Regulatory Agency in the UK (MHRA). In essence, the regulations are harmonious.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Since joining Pharmarama in early 2008 as Head of Clinical Trial Supplies, Adele Davis has been responsible for managing the operations of the company’s growing Clinical Trial Procurement Teams. She previously worked for over five years in a similar capacity and is a member of the Institute of Clinical Research. She advocates building strong relationships with customers and suppliers alike.

Educated with an Honours degree in Pharmacy from Kings College London, Amandip Sidhu is a practising pharmacist and is a member of the Royal Pharmaceutical Society and the Institute of Clinical Research. Having been instrumental in the rapid expansion of  Pharmarama’s operations since joining in March 2006, Amandip now heads up the Quality Assurance Department, which is at the core of the company’s infrastructure. Amandip is the named ‘Responsible Person’ for the organisation and also oversees all quality aspects of the company’s global operations.

spacer
Adele Davis
spacer
spacer
spacer
Amandip Sidhu
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement